Expanded Access to Venetoclax

AbbVie

Status

Conditions: Plasma Cell Leukemia; Acute Lymphoblastic Leukemia (ALL); Multiple Myeloma; Non-Hodgkin's Lymphoma; Acute Myeloid Leukemia (AML); Amyloidosis; Chronic Lymphocytic Leukemia (CLL)

Treatments: Drug: Venetoclax

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03123029

C16-431

C19-920 (Other Grant/Funding Number)

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• The participant must not be eligible for a venetoclax clinical trial.
• Pediatric participants may be evaluated on a case by case basis.